Type-B monoamine oxidase inhibitors in neurological diseases:clinical applications based on preclinical findings
Marika Alborghetti1
Edoardo Bianchini2
Lanfranco De Carolis1
Silvia Galli1
Francesco E.Pontieri2
Domiziana Rinaldi2
1.Neurology Unit,NESMOS Department,Faculty of Medicine & Psychology,Sapienza-University of Rome,Sant'Andrea University Hospital,Rome,Italy2.Neurology Unit,NESMOS Department,Faculty of Medicine & Psychology,Sapienza-University of Rome,Sant'Andrea University Hospital,Rome,Italy;Department of Clinical and Behavioral Neurology,IRCCS-Fondazione Santa Lucia,Rome,Italy
摘要：Type-B monoamine oxidase inhibitors,encompassing selegiline,rasagiline,and safinamide,are available to treat Parkinson's disease.These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease.There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson's disease,such as mood deflection,cognitive impairment,sleep disturbances,and fatigue.Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson's disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors,particularly glial cell line-derived neurotrophic factor,which support dopaminergic neurons.Besides,safinamide may interfere with neurodegenerative mechanisms,counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity.Due to the dual mechanism of action,the new generation of type-B monoamine oxidase inhibitors,including safinamide,is gaining interest in other neurological pathologies,and many supporting preclinical studies are now available.The potential fields of application concern epilepsy,Duchenne muscular dystrophy,multiple sclerosis,and above all,ischemic brain injury.The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline,rasagiline,and safinamide in Parkinson's disease and beyond,focusing on possible future therapeutic applications.
机标关键词：applicationsinhibitorsbaseddiseasesfindingsmonoamineneurologicaloxidase
论文发表日期：2024-01-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 16-21 )
英文信息